"A turning point in research" for future anti-aging drugs - Greatly boosted seniors immune function

01/05/2015 - 00:00

By Dennis Thompson -

The study is a "watershed" moment for research into the health effects of aging, said Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine in New York City.

Rapamycin belongs to a class of drugs known as mTOR inhibitors, which have been shown to counteract aging and aging-related diseases in mice and other animals.